Safety considerations for inotuzumab in patients with relapsed/refractory ALL

HER2CLIMB: Investigating tucatinib with capecitabine and trastuzumab in HER2-positive metastatic breast cancer

Novel therapeutic approaches in B-progenitor ALL

Latest concepts in frontline therapy for paediatric ALL

Recognising the value of European cancer nurses

Improvements in patient safety: Encouraging patient-reporting of symptoms

Improving cancer care in the UK

Dasatinib vs imatinib in the treatment of paediatric ALL

Lenalidomide maintenance for transplant eligible and transplant ineligible newly diagnosed myeloma patients

Is enasidenib plus azacitidine better than with azacitidine alone for AML patients?

Exploring adjuvant endocrine therapy use with letrozole in postmenopausal women with hormone receptor-positive breast cancer

Cisplatin versus doxorubicin/cyclophosphamide as neoadjuvant treatment in germline BRCA carriers with HER2-negative BC